Abstract
Since their initial description in 1992, neurospheres have appeared in some aspect of more than a thousand published studies. Despite their ubiquitous presence in the scientific literature, there is little consensus regarding the fundamental defining characteristics of neurospheres; thus, there is little agreement about what, if anything, the neurosphere assay can tell us about the relative abundance or behavior of neural stem cells in vivo. In this review we will examine some of the common features of neurospheres, and ask if these features should be interpreted as a proxy for neural stem cells. In addition, we will discuss ways in which the neurosphere assay has been used to evaluate in vivo treatment/manipulation, and will suggest appropriate ways in which neurosphere data should be interpreted, vis-a-vis the neural stem cell. Finally, we will discuss a relatively new in vitro approach, the Neural-Colony Forming Cell Assay, which provides a more meaningful method of quantifying bona fide neural stem cells without conflating them with more growth-restricted progenitor cells.
Keywords: Neurosphere, neural stem cell, stem cell assay
Current Pharmaceutical Biotechnology
Title: Using the Neurosphere Assay to Quantify Neural Stem Cells In Vivo
Volume: 8 Issue: 3
Author(s): Gregory P. Marshall, Brent A. Reynolds and Eric D. Laywell
Affiliation:
Keywords: Neurosphere, neural stem cell, stem cell assay
Abstract: Since their initial description in 1992, neurospheres have appeared in some aspect of more than a thousand published studies. Despite their ubiquitous presence in the scientific literature, there is little consensus regarding the fundamental defining characteristics of neurospheres; thus, there is little agreement about what, if anything, the neurosphere assay can tell us about the relative abundance or behavior of neural stem cells in vivo. In this review we will examine some of the common features of neurospheres, and ask if these features should be interpreted as a proxy for neural stem cells. In addition, we will discuss ways in which the neurosphere assay has been used to evaluate in vivo treatment/manipulation, and will suggest appropriate ways in which neurosphere data should be interpreted, vis-a-vis the neural stem cell. Finally, we will discuss a relatively new in vitro approach, the Neural-Colony Forming Cell Assay, which provides a more meaningful method of quantifying bona fide neural stem cells without conflating them with more growth-restricted progenitor cells.
Export Options
About this article
Cite this article as:
Gregory P. Marshall , Brent A. Reynolds and Eric D. Laywell , Using the Neurosphere Assay to Quantify Neural Stem Cells In Vivo, Current Pharmaceutical Biotechnology 2007; 8 (3) . https://dx.doi.org/10.2174/138920107780906559
DOI https://dx.doi.org/10.2174/138920107780906559 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crocetin, a Carotenoid Derivative, Inhibits VEGF-Induced Angiogenesis via Suppression of p38 Phosphorylation
Current Neurovascular Research Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease
Current Neuropharmacology Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
Anti-Cancer Agents in Medicinal Chemistry State of the Art Molecular Pharmacology, Pathogenesis and Epigenetics of 3 Major Cancers: Lung Cancer, Ovarian Cancer, and Gliomas
Current Molecular Pharmacology Editorial [Hot Topic: Designing New Drugs For High Grade Gliomas (Executive Guest Editor: Guido Frosina)]
Current Pharmaceutical Design Modified cAMP Derivatives: Powerful Tools in Heart Research
Current Medicinal Chemistry Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Targeting of Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Herpes Simplex Virus Type 1-Based Amplicons Vectors (Guest Editor: Alberto L. Epstein)]
Current Gene Therapy Exploring Nanotechnologies for the Effective Therapy of Malaria Using Plant-Based Medicines
Current Pharmaceutical Design Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Expression of P-gp in Glioblastoma: What we can Learn from Brain Development
Current Pharmaceutical Design Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry Compounds from Wild Mushrooms with Antitumor Potential
Anti-Cancer Agents in Medicinal Chemistry Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry